Abstract
Genomics holds promise for precision treatment and identifying the primary tissue of origin (TOO) in cases of cancer of unknown primary (CUP). We evaluated the feasibility and diagnostic superiority of whole genome and transcriptome sequencing (WGTS) over conventional panel testing in 72 patients using routine pathology samples. WGTS not only detected all reportable mutations identified by panel testing but also uncovered additional clinically relevant features in 76% of cases. Utilizing a CUP prediction algorithm (CUPPA) trained on WGTS data of known primary cancers, WGTS informed TOO in 77% of cases. Importantly, WGTS suggested potential treatment options for 79% of patients, a significant improvement over the 62% informed by panel testing. Additionally, WGTS and CUPPA applied to 22 cell-free DNA samples yielded high-likelihood TOO predictions in 41% of cases. These findings demonstrate that WGTS is diagnostically superior to panel testing, broadens treatment options, and is feasible using archived tissues and cell-free DNA.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was supported by funding from Australian Health Genome Alliance (AGHA) and National Health and Medical Research council (NHMRC) (1113531) and the Medical Research Future Fund (MRFF, GHFMCDI000003). RWT was supported by funding from the Victorian Cancer Agency (TP828750). The Westmead, Blacktown, and Nepean study sites were supported by the Cancer Institute NSW 11/TRC/1-06, 15/TRC/1-01, and 15/RIG/1-16.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of Peter MacCallum Cancer Centre gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
The datasets generated during and/or analysed during the current study are available in the European genome archive (EGA) repository, [EGAS50000000452]. Data is available from the EGA upon reasonable request. All analysed and curated data during this study are included in this published article (and its supplementary information files).